These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33761130)

  • 1. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease.
    Rosenwasser N; Lee D; Sidbury R; Zhao Y
    Paediatr Drugs; 2021 Mar; 23(2):131-141. PubMed ID: 33761130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
    Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
    Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
    Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
    J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
    Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
    Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
    Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
    Peer FC; Miller A; Pavli P; Subramaniam K
    Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
    Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
    JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
    Nidegger A; Mylonas A; Conrad C
    Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
    Melo FJ; Magina S
    Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
    Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
    Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
    Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature.
    Yang C; Rosenwasser N; Wang X; Xu Z; Scheck J; Boos MD; Gupta D; Brandling-Bennet HA; Sidbury R; Iyer RS; Zhao Y
    Paediatr Drugs; 2023 Sep; 25(5):603-611. PubMed ID: 37479948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA.
    Zhao Y; Sullivan E; Son MB; Beukelman T
    Ann Rheum Dis; 2022 May; 81(5):662-665. PubMed ID: 35086815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
    Thein D; Egeberg A; Skov L; Loft N
    JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
    Wu J; Smogorzewski J
    Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.